Clinical Trials Logo

Chronic Kidney Failure clinical trials

View clinical trials related to Chronic Kidney Failure.

Filter by:

NCT ID: NCT00694824 Completed - Inflammation Clinical Trials

Vascular Calcification's Risk Factors in Haemodialysis Patients

Start date: November 2004
Phase:
Study type: Observational

A not randomized , cross sectional study will be done to determine the possible association of coronary artery calcification (CAC) score assessed by multirow spiral computed tomography (MSCT) with specific and non specific uremic factor of vascular calcification.

NCT ID: NCT00659724 Completed - Clinical trials for Chronic Kidney Failure

Ease of Use and Blood Clotting for the Gambro Polyflux HD-C4 Big Dialyzer

Start date: March 2008
Phase: N/A
Study type: Observational

The purpose of this study is to collect information on the ease of use and thrombogenicity of the Polyflux HD-C4 Big and Fresenius Optiflux 180NR or 200NR dialyzers under conditions of routine clinical use for hemodialysis.

NCT ID: NCT00436683 Completed - Clinical trials for Chronic Kidney Failure

Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia

ACT3
Start date: February 2007
Phase: Phase 2
Study type: Interventional

Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study is to determine how well a range of different doses of fermagate are tolerated by the subjects in the trial.

NCT ID: NCT00391287 Completed - Clinical trials for Chronic Kidney Failure

Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure

PRIMS
Start date: June 2006
Phase: Phase 4
Study type: Observational

The purpose of this study is to estimate the incidence rate of pure red cell aplasia (PRCA; aplastic anemia) mediated by erythropoietin (EPO) antibodies in patients who are receiving subcutaneous (s.c.) epoetin alfa (polysorbate 80 formulation) for the treatment of anemia associated with chronic renal failure (CRF), and to compare this incidence rate to the incidence rate with s.c. exposure to other currently marketed recombinant erythropoietin products (epoetin alfa, epoetin beta, darbepoetin alfa), with adjustment of duration for which the drug is given to the patient. The study will also examine the impact of the pattern of using mixed s.c. exposure to multiple erythropoietin products occurring in this patients, and the impact of the time from which the treatment is started to the onset of PRCA.

NCT ID: NCT00358306 Completed - Clinical trials for Endothelial Dysfunction

The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)

Start date: April 2008
Phase:
Study type: Observational

To understand how AKI (Acute Kidney Injury) leads to chronic kidney disease so therapies can be found to alter the progression of events thereby significantly impacting the long-term outcomes of children who develop AKI.

NCT ID: NCT00317694 Completed - Clinical trials for Chronic Kidney Failure

Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients

Start date: March 2006
Phase: Phase 2
Study type: Interventional

Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study it to look at how effective and safe Magnesium iron hydroxycarbonate is in controlling levels of phosphate in the blood in patients who receive hemodialysis.

NCT ID: NCT00256750 Completed - Clinical trials for Kidney Transplantation

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)

BENEFIT
Start date: March 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to learn if Belatacept can provide protection from organ rejection following kidney transplantation while avoiding some of the toxic effects of standard immunosuppressive medications such as kidney damage. Effects on kidney function and patient survival as well as drug safety will also be studied.

NCT ID: NCT00211900 Completed - Clinical trials for Chronic Kidney Failure

Evaluation of Manufacturing Lot of StaphVAX

Start date: March 2005
Phase: Phase 3
Study type: Interventional

This study answers a U.S. Food and Drug Administration requirement for evaluation in people of a manufacturing lot of vaccine. Subjects receive one dose of one lot of vaccine. The antibodies in the blood measure the immunogenicity of the vaccine, and typical vaccine safety information is also collected.

NCT ID: NCT00153621 Completed - HIV Infections Clinical Trials

Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients

Start date: September 2004
Phase: N/A
Study type: Observational

Among adults with Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS), Chronic Kidney Disease (CKD) has previously been reported to occur in approximately 10% of children with HIV-infection. The frequency of CKD, its causes, and its natural history in children and adolescents with HIV-infection have not been systematically studied, particularly in the era of new anti-retroviral medications. The primary aim of this study is to determine the how common pediatric HIV-infected individuals have evidence of persistent proteinuria and CKD.

NCT ID: NCT00074620 Completed - Clinical trials for Chronic Kidney Failure

A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis

Start date: November 2003
Phase: Phase 2
Study type: Interventional

The study will look at the safety profile (unwanted effects) of the long-lasting anticoagulant PEG-hirudin (SPP200) and compare these unwanted effects to those of unfractionated heparin, commonly used in haemodialysis to avoid clotting of the graft and of the haemodialysis machine.